Sai-Hong Ignatius Ou Selected Research

Crizotinib

3/2022	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.
1/2022	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
1/2021	Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
1/2021	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
1/2021	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
1/2021	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
1/2020	Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
1/2020	Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases.
1/2020	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
1/2020	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sai-Hong Ignatius Ou Research Topics

Disease

85	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 08/2008
55	Neoplasms (Cancer) 10/2022 - 01/2007
25	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2012
17	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2014
15	Disease Progression 03/2022 - 06/2015
5	Adenocarcinoma of Lung 03/2022 - 05/2012
5	Brain Neoplasms (Brain Tumor) 10/2018 - 09/2014
5	Adenocarcinoma 01/2017 - 10/2011
4	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 05/2013
4	Carcinoma (Carcinomatosis) 02/2021 - 05/2015
4	Stomach Neoplasms (Stomach Cancer) 05/2015 - 05/2013
3	Necrosis 01/2020 - 06/2015
3	Central Nervous System Diseases (CNS Diseases) 01/2018 - 12/2016
3	Fatigue 09/2014 - 01/2011
2	Nausea 01/2021 - 02/2012
2	Diarrhea 01/2021 - 02/2012
2	Glioma (Gliomas) 01/2020 - 01/2017
2	Thyroid Neoplasms (Thyroid Cancer) 01/2018 - 01/2017
2	Bradycardia 04/2016 - 12/2011
2	Pleural Effusion (Pleural Effusions) 09/2014 - 05/2012
2	Pneumonia (Pneumonitis) 02/2012 - 01/2011
2	Vision Disorders (Hemeralopia) 02/2012 - 01/2011
1	Carcinogenesis 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2020
1	Refractive Errors (Refractive Error) 01/2020
1	Osteosarcoma (Osteogenic Sarcoma) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Hepatitis 01/2019
1	Residual Neoplasm 05/2018
1	Papillary Thyroid Cancer 01/2018
1	Pain (Aches) 01/2018
1	Cough 01/2018
1	medullary Thyroid cancer 01/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017
1	Melanoma (Melanoma, Malignant) 01/2017

Drug/Important Bio-Agent (IBA)

56	CrizotinibIBA 03/2022 - 12/2010
39	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2011
26	Tyrosine Kinase InhibitorsIBA 01/2022 - 08/2010
24	alectinibIBA 01/2022 - 09/2014
14	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2010
12	Phosphotransferases (Kinase)IBA 01/2020 - 04/2012
10	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 03/2012
9	lorlatinibIBA 01/2022 - 01/2017
6	osimertinibIBA 01/2022 - 01/2016
6	Pharmaceutical PreparationsIBA 01/2020 - 02/2012
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 06/2015
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 12/2014
5	Proto-Oncogene Proteins c-metIBA 01/2017 - 05/2013
4	Circulating Tumor DNAIBA 01/2020 - 01/2017
4	SolventsIBA 12/2019 - 01/2017
3	Monoclonal AntibodiesIBA 01/2022 - 09/2015
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2015
3	brigatinibIBA 05/2021 - 10/2018
3	Tyrosine (L-Tyrosine)FDA Link 01/2020 - 01/2011
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 01/2017
2	adagrasibIBA 10/2022 - 01/2020
2	LigandsIBA 01/2022 - 02/2021
2	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2020
2	PlatinumIBA 01/2022 - 03/2015
2	ceritinibIBA 05/2021 - 01/2017
2	Epidermal Growth Factor (EGF)IBA 02/2021 - 05/2013
2	entrectinibIBA 01/2021 - 01/2017
2	Alanine Transaminase (SGPT)IBA 01/2021 - 01/2011
2	cabozantinibIBA 01/2021 - 01/2017
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 05/2013
2	Formaldehyde (Formol)FDA Link 01/2018 - 01/2018
2	ParaffinIBA 01/2018 - 01/2018
2	AfatinibIBA 01/2017 - 05/2012
2	Trastuzumab (Herceptin)FDA Link 08/2013 - 06/2013
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	amivantamab-vmjwIBA 01/2022
1	aumolertinibIBA 01/2022
1	sotorasibIBA 12/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	taletrectinibIBA 01/2020
1	Retinaldehyde (Retinal)IBA 01/2020
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 01/2020
1	Pemetrexed (MTA)FDA Link 01/2019
1	rociletinibIBA 11/2018
1	Cyclin-Dependent Kinase Inhibitor p15IBA 10/2018
1	Co-Repressor ProteinsIBA 10/2018
1	repotrectinibIBA 10/2018
1	Cyclin-Dependent Kinase Inhibitor p16IBA 10/2018
1	pralsetinibIBA 01/2018
1	trametinibIBA 01/2018
1	dabrafenibIBA 01/2018
1	SmokeIBA 01/2017
1	Etoposide (VP 16)FDA LinkGeneric 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017

Therapy/Procedure

31	Therapeutics 01/2022 - 05/2013
12	Drug Therapy (Chemotherapy) 01/2022 - 10/2009
3	Radiotherapy 10/2018 - 09/2013
3	Precision Medicine 10/2018 - 06/2013
3	Molecular Targeted Therapy 09/2012 - 01/2011
2	Aftercare (After-Treatment) 01/2017 - 01/2017
1	Immunotherapy 01/2021
1	Slit Lamp 01/2020